GE Healthcare announced on Monday plans to co-develop digital clinical decision support solutions with the pharmaceutical and diagnostic company Roche.

“As we look to create new digital tools and software to enable doctors to provide more effective patient care and treatment plans, we are impressed by Roche’s expertise and fluency in the highly regulated industry, as evidenced by their participation in the FDA PreCert program,” John Lin, executive global strategy leader at GE, told HCB News.

In vivo data from GE’s medical imaging and monitoring equipment and in vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio will be used to create a digital platform. It will comprise workflow solutions and apps that help physicians make decisions when caring for cancer and critical care patients.

The plan is to develop a comprehensive data dashboard for oncology care teams with multiple specialists. It will allow them to review the data and collaborate on making treatment decisions for cancer patients at each stage of their disease.

For the critical care setting, data from the patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data to help physicians identify or predict severe complications.

“While an old term, the field of digital clinical decision support is only now undergoing a renaissance, enabled by the digitization of health records, cloud computing and advanced analytics,” said Lin.

The global clinical decision support system market is expected to grow at a compound annual growth rate of over 21 percent from 2016 to 2022 and reach more than $1.5 billion, according to an Acumen Research and Consulting report from November 2017.

The report explained that leading players are sustaining market competition by forming strategic relationships to share existing, and developing new, technology.

Health IT Homepage